BeyondSpring Inc BYSI shares are trading higher by 22.5% at $26.59 Friday afternoon on continued strength after the company earlier in the week announced results from its DUBLIN-3 trial of plinabulin in combination with docetaxel, which met its primary endpoint.
See Also: BeyondSpring CEO Talks Better-Than-Expected Trial Results That Sent The Stock Soaring
BeyondSpring is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies.
BeyondSpring is also focused on including immuno-oncology agents. The company has created Plinabulin which is a marine-derived small molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities.
BeyondSpring has a 52-week high of $30.01 and a 52-week low of $8.90.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
